RSV Vaccine for People Over 60 Gains Full Approval
Medically reviewed by Drugs.com.
By Physician’s Briefing Staff HealthDay Reporter
THURSDAY, June 29, 2023 -- Americans ages 60 and up can get their vaccine for respiratory syncytial virus (RSV) this fall, the U.S. Centers for Disease Control and Prevention has announced.
On Thursday, Rochelle Walensky, M.D., the outgoing CDC director, gave her signature to a recommendation made last week by an advisory panel of outside experts for a single dose of the vaccines made by Pfizer and GlaxoSmithKline. The U.S. Food and Drug Administration sanctioned the shots last month for adults 60 and older. The CDC added in a statement that it is advising seniors to first consult with their doctors to determine if the vaccine is right for them.
While some, including Robert Blancato, executive director of the National Association of Nutrition and Aging Services Programs, wanted the CDC to give a stronger vaccine recommendation for those ages 65 and up, the advisory panel offered the weaker endorsement after raising questions, the Associated Press reported. Those included how well the vaccine worked in those who were most frail, whether there might be a need for boosters and costs.
Pfizer has not revealed their pricing plan. GSK plans to charge between $200 and $295 a shot.
RSV can appear like the common cold, but can be dangerous for infants, children and the elderly, the AP reported. Those adults considered most at risk have chronic heart or lung disease, a weakened immune system, or live in a long-term care facility.
For more information see What is the difference between Arexvy and Abrysvo?
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Read this next
Personalized Tool Can Predict Infants at Increased Risk for RSV
THURSDAY, May 9, 2024 -- A personalized tool can predict infants at increased risk for severe respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) who would...
Most Moms-to-Be Interested in RSV Vaccination During Pregnancy
THURSDAY, April 25, 2024 -- More than half of women who are pregnant or planning to become pregnant are very likely to get vaccinated against respiratory syncytial virus (RSV)...
RSV Burden in Children Under 5 Increased in 2021 and 2022 Versus 2015-2019
FRIDAY, April 19, 2024 -- For children younger than 5 years, the incidence of respiratory syncytial virus (RSV) hospitalization increased in 2021 and 2022 compared with 2015 to...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.